rAbDesFlow: A novel workflow for computational recombinant antibody design for healthcare engineering

Q2 Medicine
Sowmya Ramaswamy Krishnan, Divya Sharma, Yasin Nazeer, Mayilvahanan Bose, Thangarajan Rajkumar, Guhan Jayaraman, Narayanan Madaboosi, M. M. Gromiha
{"title":"rAbDesFlow: A novel workflow for computational recombinant antibody design for healthcare engineering","authors":"Sowmya Ramaswamy Krishnan, Divya Sharma, Yasin Nazeer, Mayilvahanan Bose, Thangarajan Rajkumar, Guhan Jayaraman, Narayanan Madaboosi, M. M. Gromiha","doi":"10.1093/abt/tbae018","DOIUrl":null,"url":null,"abstract":"\n \n \n Recombinant antibodies have emerged as a promising solution to tackle antigen specificity, enhancement of immunogenic potential and versatile functionalization to treat human diseases. The development of single chain variable fragments (scFv) has helped accelerate treatment in cancers and viral infections, due to their favorable pharmacokinetics and human compatibility. However, designing recombinant antibodies is traditionally viewed as a genetic engineering problem, with phage display and cell free systems playing a major role in sequence selection for gene synthesis. The process of antibody engineering involves complex and time-consuming laboratory techniques, which demand substantial resources and expertise. The success rate of obtaining desired antibody candidates through experimental approaches can be modest, necessitating iterative cycles of selection and optimization. With ongoing advancements in technology, in silico design of diverse antibody libraries, screening and identification of potential candidates for in vitro validation can be accelerated.\n \n \n \n To meet this need, we have developed rAbDesFlow, a unified computational workflow for recombinant antibody engineering with open-source programs and tools for ease of implementation.\n \n \n \n The workflow encompasses five computational modules to perform antigen selection, antibody library generation, antigen and antibody structure modeling, antigen-antibody interaction modeling, structure analysis, and consensus ranking of potential antibody sequences for synthesis and experimental validation. The proposed workflow has been demonstrated through design of recombinant antibodies for the ovarian cancer antigen Mucin-16 (CA-125).\n \n \n \n This approach can serve as a blueprint for designing similar engineered molecules targeting other biomarkers, allowing for a simplified adaptation to different cancer types or disease-specific antigens.\n","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibody Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/abt/tbae018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Recombinant antibodies have emerged as a promising solution to tackle antigen specificity, enhancement of immunogenic potential and versatile functionalization to treat human diseases. The development of single chain variable fragments (scFv) has helped accelerate treatment in cancers and viral infections, due to their favorable pharmacokinetics and human compatibility. However, designing recombinant antibodies is traditionally viewed as a genetic engineering problem, with phage display and cell free systems playing a major role in sequence selection for gene synthesis. The process of antibody engineering involves complex and time-consuming laboratory techniques, which demand substantial resources and expertise. The success rate of obtaining desired antibody candidates through experimental approaches can be modest, necessitating iterative cycles of selection and optimization. With ongoing advancements in technology, in silico design of diverse antibody libraries, screening and identification of potential candidates for in vitro validation can be accelerated. To meet this need, we have developed rAbDesFlow, a unified computational workflow for recombinant antibody engineering with open-source programs and tools for ease of implementation. The workflow encompasses five computational modules to perform antigen selection, antibody library generation, antigen and antibody structure modeling, antigen-antibody interaction modeling, structure analysis, and consensus ranking of potential antibody sequences for synthesis and experimental validation. The proposed workflow has been demonstrated through design of recombinant antibodies for the ovarian cancer antigen Mucin-16 (CA-125). This approach can serve as a blueprint for designing similar engineered molecules targeting other biomarkers, allowing for a simplified adaptation to different cancer types or disease-specific antigens.
rAbDesFlow:用于医疗保健工程的计算重组抗体设计的新型工作流程
重组抗体已成为解决抗原特异性、增强免疫原性和多功能化治疗人类疾病的一种有前途的解决方案。由于单链可变片段(scFv)具有良好的药代动力学和人体相容性,它的开发有助于加速癌症和病毒感染的治疗。然而,重组抗体的设计传统上被视为基因工程问题,噬菌体展示和无细胞系统在基因合成的序列选择中发挥着重要作用。抗体工程过程涉及复杂耗时的实验室技术,需要大量的资源和专业知识。通过实验方法获得所需的抗体候选物的成功率可能很低,需要反复循环进行选择和优化。随着技术的不断进步,可以加快对多样化抗体库进行硅学设计、筛选和鉴定潜在候选抗体以进行体外验证的速度。 为了满足这一需求,我们开发了 rAbDesFlow,这是一种统一的重组抗体工程计算工作流程,采用开源程序和工具,易于实施。 该工作流程包括五个计算模块,分别用于抗原选择、抗体库生成、抗原和抗体结构建模、抗原抗体相互作用建模、结构分析以及潜在抗体序列的共识排序,以便进行合成和实验验证。通过设计卵巢癌抗原粘蛋白-16(CA-125)的重组抗体,演示了所提出的工作流程。 这种方法可以作为设计针对其他生物标志物的类似工程分子的蓝图,从而简化对不同癌症类型或特定疾病抗原的适应性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antibody Therapeutics
Antibody Therapeutics Medicine-Immunology and Allergy
CiteScore
8.70
自引率
0.00%
发文量
30
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信